Susan Woody, DO
Nephrology · Springfield, MONPI 1053408484
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,550 of the $4,575 with a category attached, or 77.6%. AstraZeneca accounts for 84.2% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2020 at $2,594 and has fallen 96.9% since, to $81 in 2025.
Across 58 payments — averaging $78.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- Akebia Therapeutics Inc$123
- Otsuka America Pharmaceutical, Inc.$119
- Fresenius USA Marketing, Inc.$99
- Otsuka Pharmaceutical Development & Commercialization, Inc.$63
- Bard Peripheral Vascular, Inc.$55
- plus $263 from 12 others
What the payments were for
- Speaking & faculty fees$3,55078%
- Food & beverage$99522%
- Education$301%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LOKELMA$3,550
How this compares
$4,575 in reported general payments places this provider in the 80th percentile of 253 nephrology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AuryxiaFerric Citrate | 46 | $84,666 |
| Lanthanum Carbonate | 50 | $50,480 |
| FosrenolLanthanum Carbonate | 20 | $38,099 |
| Sevelamer Carbonate | 102 | $12,883 |
| Calcium Acetate | 45 | $3,982 |
| Bumetanide | 51 | $2,245 |
| Torsemide | 44 | $1,347 |
| Calcitriol | 118 | $1,212 |
| Nifedipine ErNifedipine | 37 | $954 |
| Potassium Chloride | 51 | $797 |
| Doxazosin Mesylate | 39 | $645 |
| Bethanechol Chloride | 13 | $623 |
| Hydralazine Hcl | 80 | $562 |
| Amlodipine Besylate | 156 | $547 |
| Tamsulosin Hcl | 61 | $491 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Akebia Therapeutics IncAuryxia | $123 | $84,66646 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 253 nephrology providers in Missouri.
Other nephrology in Springfield
- Giselle KohlerSpringfield$7K
- David SommerfeldSpringfield$3K
- Derek LarsonCreve Coeur$605K
- Marcos RothsteinSaint Louis$350K
- Anuja JavaSaint Louis$240K
- Kevin MartinSt Louis$189K
- Alejandro AlvarezFlorissant$176K
- Gary SingerSaint Peters$170K
- Daniel CoyneSaint Louis$163K
- Tarek AlhamadSaint Louis$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.